Human Vδ1 γδ T cells expanded from peripheral blood exhibit specific cytotoxicity against B-cell chronic lymphocytic leukemia-derived cells

References

• Kabelitz D, Wesch D, He W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 2007;67:5–8.
   PubMed Web of Science ®Google Scholar
• De Rosa SC, Andrus JP, Perfetto SP, Mantovani JJ, Herzenberg LA, Roederer M. Ontogeny of gamma delta T cells in humans. J Immunol. 2004;172:1637–45.
   PubMed Web of Science ®Google Scholar
• Hviid L, Akanmori BD, Loizon S, Kurtzhals JA, Ricke CH, Lim A, . High frequency of circulating gamma delta T cells with dominance of the V(delta)1 subset in a healthy population. Int Immunol. 2000;12:797–805.
   PubMed Web of Science ®Google Scholar
• Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975–1026.
   PubMed Web of Science ®Google Scholar
• Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, . Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999;285:727–9.
   PubMed Web of Science ®Google Scholar
• Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, . Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science. 1994;264:267–70.
   PubMed Web of Science ®Google Scholar
• Morita CT, Lee HK, Leslie DS, Tanaka Y, Bukowski JF, Marker-Hermann E. Recognition of nonpeptide prenyl pyrophosphate antigens by human gammadelta T cells. Microbes Infect. 1999;1:175–86.
   Google Scholar
• Burk MR, Mori L, De Libero G. Human V gamma 9-V delta 2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites. Eur J Immunol. 1995;25:2052–8.
   PubMed Web of Science ®Google Scholar
• Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M, . In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175: 5471–80.
   PubMed Web of Science ®Google Scholar
• Bukowski JF, Morita CT, Brenner MB. Human gamma delta T cells recognize alkylamines derived from microbes, edible plants, and tea: implications for innate immunity. Immunity. 1999;11:57–65.
   PubMed Web of Science ®Google Scholar
• Spada FM, Grant EP, Peters PJ, Sugita M, Melian A, Leslie DS, . Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity. J Exp Med. 2000;191:937–48.
   PubMed Web of Science ®Google Scholar
• Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, . ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001; 14:123–33.
   PubMed Web of Science ®Google Scholar
• Ensslin AS, Formby B. Comparison of cytolytic and proliferative activities of human gamma delta and alpha beta T cells from peripheral blood against various human tumor cell lines. J Natl Cancer Inst. 1991;83:1564–9.
   PubMedGoogle Scholar
• Fisch P, Meuer E, Pende D, Rothenfusser S, Viale O, Kock S, . Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. Eur J Immunol. 1997;27: 3368–79.
   PubMed Web of Science ®Google Scholar
• Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P. Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol. 2002;215:32–44.
   Google Scholar
• Dolstra H, Fredrix H, van der Meer A, de Witte T, Figdor C, van de Wiel-van Kemenade E. TCR gamma delta cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. Bone Marrow Transplant. 2001;27:1087–93.
   PubMed Web of Science ®Google Scholar
• Wright A, Lee JE, Link MP, Smith SD, Carroll W, Levy R, . Cytotoxic T lymphocytes specific for self tumor immunoglobulin express T cell receptor delta chain. J Exp Med. 1989;169:1557–64.
   PubMed Web of Science ®Google Scholar
• Vollenweider I, Vrbka E, Fierz W, Groscurth P. Heterogeneous binding and killing behaviour of human gamma/delta-TCR+ lymphokine-activated killer cells against K562 and Daudi cells. Cancer Immunol Immunother. 1993;36:331–6.
   PubMed Web of Science ®Google Scholar
• Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384–92.
   PubMed Web of Science ®Google Scholar
• Choudhary A, Davodeau F, Moreau A, Peyrat MA, Bonneville M, Jotereau F. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma. J Immunol. 1995;154:3932–40.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother. 2001;50:115–24.
   PubMed Web of Science ®Google Scholar
• Maeurer MJ, Martin D, Walter W, Liu K, Zitvogel L, Halusczcak K, . Human intestinal Vdelta1 + lymphocytes recognize tumor cells of epithelial origin. J Exp Med. 1996; 183:1681–96.
   PubMed Web of Science ®Google Scholar
• Chen J, Niu H, He W, Ba D. Antitumor activity of expanded human tumor-infiltrating gammadelta T lymphocytes. Int Arch Allergy Immunol. 2001;125:256–63.
   PubMed Web of Science ®Google Scholar
• Hacker G, Kromer S, Falk M, Heeg K, Wagner H, Pfeffer K. V delta 1+ subset of human gamma delta T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B lymphocytes. J Immunol. 1992;149: 3984–9.
   PubMed Web of Science ®Google Scholar
• Duval M, Yotnda P, Bensussan A, Oudhiri N, Guidal C, Rohrlich P, . Potential antileukemic effect of gamma delta T cells in acute lymphoblastic leukemia. Leukemia. 1995;9: 863–8.
   PubMed Web of Science ®Google Scholar
• Meeh PF, King M, O'Brien RL, Muga S, Buckhalts P, Neuberg R, . Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother. 2006;55:1072–80.
   PubMed Web of Science ®Google Scholar
• Aswald JM, Wang XH, Aswald S, Lutynski A, Minden MD, Messner HA, . Flow cytometric assessment of autologous gammadelta T cells in patients with acute myeloid leukemia: potential effector cells for immunotherapy? Cytometry B Clin Cytom. 2006;70:379–90.
   PubMed Web of Science ®Google Scholar
• Lamb LS Jr, Gee AP, Hazlett LJ, Musk P, Parrish RS, O'Hanlon TP, . Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy. 1999;1: 7–19.
   PubMed Web of Science ®Google Scholar
• Lamb LS Jr, Musk P, Ye Z, van Rhee F, Geier SS, Tong JJ, . Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplant. 2001;27:601–6.
   Google Scholar
• Bartkowiak J, Kulczyck-Wojdala D, Blonski JZ, Robak T. Molecular diversity of gammadelta T cells in peripheral blood from patients with B-cell chronic lymphocytic leukaemia. Neoplasma. 2002;49:86–90.
   Google Scholar
• Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, . Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004;64:9172–9.
   PubMed Web of Science ®Google Scholar
• Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333:1052–7.
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Pereira A, Rozman C, Aymerich M, Gine E, Moreno C, . Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114:2044–50.
   PubMed Web of Science ®Google Scholar
• Foster AE, Brenner MK, Dotti G. Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2008;21:375–89.
   PubMed Web of Science ®Google Scholar
• Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, . A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg. 2010;37:1191–7.
   PubMed Web of Science ®Google Scholar
• Lucas C, Ingoure S, Soule E, Faria B, Audibert F, Blery M, . IPH1101, the first specific gamma delta T cell agonist, shows potent immuno-biological efficacy in low grade follicular lymphoma patients when combined with rituximab: results from a phase II study. Blood. 2009;114:583.
   Web of Science ®Google Scholar
• Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, . Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med. 1990;171: 1567–79.
   PubMed Web of Science ®Google Scholar
• Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol. 2005;23: 108–16.
   PubMed Web of Science ®Google Scholar
• Yoshimitsu M, Sato T, Tao K, Walia JS, Rasaiah VI, Sleep GT, . Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc Natl Acad Sci USA. 2004;101: 16909–14.
   PubMed Web of Science ®Google Scholar
• Tohda S, Nara N, Murohashi I, Aoki N. Establishment of an interleukin-3-dependent leukemic cell line from a patient with chronic lymphocytic leukemia in the acute phase. Blood. 1991;78:1789–94.
   PubMed Web of Science ®Google Scholar
• McCoy JL, Herberman RB, Rosenberg EB, Donnelly FC, Levine PH, Alford C. 51 Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue-culture cells. Natl Cancer Inst Monogr. 1973;37:59–67.
   PubMedGoogle Scholar
• Siegers GM, Al-Beirouti BM, Mathieson AM, Felizardo TC, Helke S, Medin JA, . Gamma delta T cells (GDTCs) to eliminate minimal residual disease (MRD) in chronic myeloid leukemia (CML): a pre-clinical model. Blood. 2008;112: 215–6.
   PubMed Web of Science ®Google Scholar
• Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology. 2007;121:439–47.
   PubMed Web of Science ®Google Scholar
• Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS, . Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett. 2010;297:126–36.
   Google Scholar
• Chang CP, Yang MC, Liu HS, Lin YS, Lei HY. Concanavalin A induces autophagy in hepatoma cells and has a therapeutic effect in a murine in situ hepatoma model. Hepatology. 2007; 45:286–96.
   PubMed Web of Science ®Google Scholar
• Liu Z, Li X, Ding X, Yang Y. In silico and experimental studies of concanavalin A: insights into its antiproliferative activity and apoptotic mechanism. Appl Biochem Biotechnol. 2010; 162:134–45.
   PubMed Web of Science ®Google Scholar
• Liu B, Li CY, Bian HJ, Min MW, Chen LF, Bao JK. Antiproliferative activity and apoptosis-inducing mechanism of Concanavalin A on human melanoma A375 cells. Arch Biochem Biophys. 2009;482:1–6.
   PubMed Web of Science ®Google Scholar
• Forsdyke DR. Role of receptor aggregation in complement-dependent inhibition of lymphocytes by high concentrations of concanavalin A. Nature. 1977;267:358–60.
   PubMed Web of Science ®Google Scholar
• Alexander AA, Maniar A, Cummings JS, Hebbeler AM, Schulze DH, Gastman BR, . Isopentenyl pyrophosphate-activated CD56+ gamma delta T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res. 2008;14:4232–40.
   PubMed Web of Science ®Google Scholar
• Norian LA, Kucaba TA, Earel JK, Knutson T, Vanoosten RL, Griffith TS. Synergistic induction of apoptosis in primary B-CLL cells after treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand and histone deacetylase inhibitors. J Oncol. 2009;2009:408038.
   Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.
   PubMed Web of Science ®Google Scholar